SCHEMBL25751810

SCHEMBL25751810

CC(C)(C)OC(=O)NCc1nn(-c2ccc(S(F)(F)(F)(F)F)cc2)c2nccc(CO)c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 3/20 0.55
▸ TEAD4 Q15561 3/20 0.55
▸ TEAD2 Q15562 3/20 0.55
▸ TEAD3 Q99594 3/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ BRD4 O60885 3/20 0.35
▸ NAMPT P43490 2/20 0.34
▸ CCNC P24863 1/20 0.33
▸ CDK8 P49336 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ HDAC10 Q969S8 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ GLS O94925 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25751802 0.88 TEAD1 (0.43) TEAD1TEAD4TEAD2TEAD3L3MBTL1
SCHEMBL25751808 0.86 TEAD1 (0.41) TEAD1TEAD4TEAD2TEAD3L3MBTL1
SCHEMBL30423856 0.86 TEAD1 (0.58) TEAD1TEAD4TEAD2TEAD3L3MBTL1
SCHEMBL25245571 0.86 TEAD1 (0.58) TEAD1TEAD4TEAD2TEAD3L3MBTL1
SCHEMBL25751804 0.86 TEAD1 (0.41) TEAD1TEAD4TEAD2TEAD3L3MBTL1
SCHEMBL25289583 0.84 TEAD1 (0.37) TEAD1TEAD4TEAD2TEAD3L3MBTL1
SCHEMBL25209099 0.82 TEAD1 (0.54) TEAD1TEAD4TEAD2TEAD3
SCHEMBL25243401 0.80 TEAD1 (0.42) TEAD1TEAD4TEAD2TEAD3L3MBTL1
SCHEMBL30424238 0.80 TEAD1 (0.42) TEAD1TEAD4TEAD2TEAD3L3MBTL1
SCHEMBL25748055 0.79 TEAD1 (0.45) TEAD1TEAD4TEAD2TEAD3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 TEAD1 282/4885TEAD4 162/4885TEAD2 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback